Racura Oncology
Racura Oncology is a Phase 3 clinical biopharmaceutical company focused on developing cancer therapeutics. Their lead asset, RCDS1 (E,E-bisantrene), targets G4-DNA & RNA binding to inhibit MYC, a key cancer growth regulator, and is being advanced in multiple oncology indications.
Short position
Racura Oncology (ASX:RAC) has 0.01% of its shares on issue reported as short positions as of 5 Oct 2026, or about 19,354 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. RAC is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Racura Oncology (RAC) short interest history
RAC Short Interest History
- 30-day change
- 0.00pp
- 90-day change
- 0.00pp
- 1-year change
- -0.01pp
- All-time high
- 0.05% (December 2021)
- All-time low
- 0.00% (July 2024)
Is RAC heavily shorted?
Not especially: 0.01% short interest is modest by ASX standards, ranking #589 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has RAC's short interest changed recently?
Over the past 30 days Racura Oncology's short interest has been broadly stable, and over 90 days it has been broadly stable. The current level is 0.01% of shares on issue.
What is the highest RAC's short interest has been?
Since 2020, Racura Oncology's short interest peaked at 0.05% in December 2021 and bottomed at 0.00% in July 2024.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2020. See our methodology.